My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC   - Episode 7

Treatment Decision Making in first-line combinations for advanced RCC

,

The key opinion leaders explore the various first-line combination treatment options for advanced renal cell carcinoma, including immuno-oncology plus immuno-oncology (IO+IO) and immuno-oncology plus tyrosine kinase inhibitor (IO+TKI) approaches, while also considering the optimal sequencing of treatments to maximize patient benefit.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Evolving Treatment Standards in Non-Clear Cell RCC
    EP. 2: Extended Follow Up of KEYNOTE-B61
    EP. 3: Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC
    EP. 4: STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC
    EP. 5: Case Presentation: 61-year-old male Renal Cell Carcinoma
    EP. 6: Use of Combination Regimens in Frontline RCC
    Now Viewing
    EP. 7: Treatment Decision Making in first-line combinations for advanced RCC
    EP. 8: AE Management for Combination Regimens in Advanced RCC
    EP. 9: AE Management for Combination Regimens in Advanced RCC
    EP. 10: Optimizing Treatment in Advanced RCC
    EP. 11: Dr Albiges Discusses a Non-Clear Cell RCC Patient Profile
    EP. 12: Updates in the Treatment Approach for Non-clear cell RCC
    EP. 13: Dr Albiges Reviews Long term follow up data from KEYNOTE-B61
    EP. 14: Emerging Therapies in the Front-line Setting of Advanced non-clear cell RCC
    EP. 15: Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven)
    EP. 16: Summary and Forward Looking for RCC
    1. What are the available first-line combination options for advanced RCC?
      1. Please discuss your rationale for choosing between IO+IO and IO+TKI approaches and review these data: Network meta-analysis (NMA) – Grunwald, et al. ASCO GU 2024. Abstract 482 –len + pembro vs other 1L treatments in advanced RCC
    2. How do you approach treatment selection in the frontline setting?
      1. What factors do you consider when choosing treatment?
      2. Which patients do you choose len-pembro versus axi-pembro versus cabo-nivo?
    x